HCM - Hutchmed says Chinese Phase 3 sovleplenib study meets primary endpoint
2023-08-21 11:31:53 ET
More on Hutchison China MediTech
- Hutchmed: Attractive Chinese R&D Giant
- HUTCHMED (China) Limited ( HCM ) Q2 2023 Earnings Call Transcript
- Hutchmed starts registration phase for cancer trials after talks with Chinese regulator
- Hutchison China MediTech reports mixed Q4 earnings; initiates FY23 outlook
- Takeda to acquire rights to Hutchmed's cancer drug fruquintinib for $400M upfront
- AstraZeneca, Hutchmed's Orpathys included in China's national reimbursement drug list
- Seeking Alpha’s Quant Rating on Hutchison China MediTech
- Earnings data for Hutchison China MediTech
For further details see:
Hutchmed says Chinese Phase 3 sovleplenib study meets primary endpoint